Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Venus Medtech (Hangzhou)HKSE:02500 -3.64%52 Days Payable is 75.96 as of Dec. 2025, which is 68% above its 10-year median of 45.16. GuruFocus rates HKSE:02500 with a GF Score™ of 52/100 and a GF Value™ of HK$3.35 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Venus Medtech (Hangzhou) ranks better than 59.75% on this metric.
The historical rank and industry rank for Venus Medtech (Hangzhou)'s Days Payable or its related term are showing as below:
HKSE:02500'
s Days Payable Range Over the Past 10 Years
Min: 11.61 Med: 45.16 Max: 348.78
Current: 86.76
During the past 9 years, Venus Medtech (Hangzhou)'s highest Days Payable was 348.78. The lowest was 11.61. And the median was 45.16.
HKSE:02500's Days Payable is ranked better than 59.75% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs HKSE:02500: 86.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02500 vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Medtech (Hangzhou) Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Days Payable distribution charts can be found below:
* The bar in red indicates where Venus Medtech (Hangzhou)'s Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Venus Medtech (Hangzhou)'s Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Medtech (Hangzhou) (HKSE:02500) has a Days Payable of 75.96 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Venus Medtech (Hangzhou) and its competitors. This is 68% above median its historical median of 45.16. Over the past decade, Venus Medtech (Hangzhou)'s Days Payable has ranged from 11.61 to 348.78. According to the industry distribution chart, Venus Medtech (Hangzhou) ranks #320 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 40.3%.
Is Venus Medtech (Hangzhou)'s Days Payable too high?
Venus Medtech (Hangzhou)'s current Days Payable of 75.96 is 68% above median its 10-year median of 45.16. Over the past 10 years, this metric has ranged from a low of 11.61 to a high of 348.78. The Medical Devices & Instruments industry median Days Payable is 67.87. Venus Medtech (Hangzhou)'s value of 75.96 is 11.9% above this industry median. Based on the distribution chart, Venus Medtech (Hangzhou) ranks #320 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Venus Medtech (Hangzhou) ranks #320 out of 795 companies for Days Payable. This puts Venus Medtech (Hangzhou) in the upper half of its industry. The industry median Days Payable is 67.87. Venus Medtech (Hangzhou)'s value of 75.96 is 11.9% above this benchmark. Historically, Venus Medtech (Hangzhou)'s own Days Payable has ranged from 11.61 to 348.78 over the past decade. While the company's 10-year median is 45.16 vs. the industry median of 67.87, Venus Medtech (Hangzhou) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Medtech (Hangzhou)'s current Days Payable of 75.96 is 11.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Venus Medtech (Hangzhou) and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Medtech (Hangzhou)'s current Days Payable is 75.96, which is 68% above median its own 10-year median of 45.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) (HKSE:02500) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.35, compared to a current price of HK$1.06 — trading 68.4% below its estimated fair value. The current Days Payable is 75.96, which is 68% above median its 10-year median of 45.16 and 11.9% above the Medical Devices & Instruments industry median of 67.87. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (HKSE:02500), the current Days Payable is 75.96 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Medtech (Hangzhou) (HKSE:02500) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued.
The current stock price of HK$1.06 is trading 68.4% below its estimated GF Value™ of HK$3.35.
GuruFocus considers Venus Medtech (Hangzhou) to be Possible Value Trap.
Key valuation signals for HKSE:02500:
Days Payable: 75.96 (68% above median its 10-year median of 45.16)
GF Value™: HK$3.35 vs. price of HK$1.06 (68.4% below fair value)
Industry Position: 11.9% above the Medical Devices & Instruments median (#320 of 795)
No single metric tells the full story. See the HKSE:02500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score
Get the complete analysis for HKSE:02500
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02500 has been successfully added to your 
